Evidence map›Paper›PMID 40594237›Full record

ArticleScientific reports2025

A follow-up study on the novel use of contrast-enhanced susceptibility-weighted imaging for extremity desmoid fibromatosis response assessment.

Raul F Valenzuela, Elvis Duran-Sierra, Mathew Antony, Behrang Amini, Sam Lo, Keila E Torres, Ken-Pin Hwang, Jingfei Ma, R Jasson Stafford, Ravin Ratan and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Raul F ValenzuelaDepartment of Musculoskeletal Radiology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. rfvalenzuela@mdanderson.org.
Elvis Duran-SierraDepartment of Musculoskeletal Radiology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Mathew AntonyDepartment of Musculoskeletal Radiology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Behrang AminiDepartment of Musculoskeletal Radiology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Sam LoDepartment of Musculoskeletal Radiology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Keila E TorresDepartment of Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Ken-Pin HwangDepartment of Imaging Physics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Jingfei MaDepartment of Imaging Physics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
R Jasson StaffordDepartment of Imaging Physics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Ravin RatanDepartment of Sarcoma Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
John E MadewellDepartment of Musculoskeletal Radiology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Dejka AraujoDepartment of Sarcoma Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
William A MurphyDepartment of Musculoskeletal Radiology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Colleen M CostelloeDepartment of Musculoskeletal Radiology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Desmoid tumors are rare mesenchymal neoplasms characterized by a clonal proliferation of fibroblasts and myofibroblasts. Using the novel contrast-enhanced susceptibility-weighted imaging (CE-SWI) for characterizing desmoid tumors can enhance the separation between fibrous T2-hypointense and cellular T1-enhancing components. We aim to evaluate the effectiveness of the CE-SWI signal, volumetric, and radiomics-derived features in assessing desmoid treatment response. This IRB-approved study included 17 single-lesion extremity desmoid fibromatosis patients who underwent standard-of-care MRI, including CE-SWI, from March 2021 to February 2024. Measurements of maximum diameter, volume, and the modified Choi (m-Choi: tumor/muscle T2 ratio) were computed based on CE-SWI and T2-STIR volumetric tumor segmentations. 107 shape, first-order, and textural radiomic features were calculated. Patient response was assessed using conventional RECIST as a reference standard and compared against T2-STIR and CE-SWI volumetric, m-Choi, and radiomics features. RECIST-progression (n = 3): In two patients, CE-SWI volume detected progression 10 months earlier than T2-STIR-based RECIST. Only 33% were characterized as progression by the routine radiologic report (RRR). RECIST-stability (n = 14): 5% exhibited at least one expected first-order response/progression-related change in the mean, skewness, 10th percentile, or 90th percentile, with all four changes present in 33% of cases. In RECIST-progression, CE-SWI showed an average of 15% more voxels at the 90th percentile than T2-STIR. Volume and CE-SWI/T2-STIR shape-derived size dimensional features demonstrated the highest separation between progressive and responding patients. CE-SWI has a higher sensitivity than T2-WI in detecting the active/progressive enhancing component. Volume and Shape-derived and, to a lesser extent, textural radiomic features and m-Choi effectively distinguish between progressive and responding cases, outperforming first-order radiomics, RRR, and RECIST. Particularly, progression prediction by CE-SWI/T2-STIR-volume and response prediction by CE-SWI-m-Choi outperform and precede RRR and RECIST. The novel CE-SWI enhances tumor insight and desmoid treatment-response prediction by effectively separating responding T2-hypointense-collagenized-mature components from potentially progressive T1-shortened/enhancing T2-hyperintense-immature components.

Indexed as

Contrast MediaDesmoid TumorsExtremitiesMagnetic Resonance ImagingAdolescentAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedYoung AdultContrast MediaContrast-enhanced susceptibility imaging (CE-SWI)Desmoid-FibromatosisMultiparametric MRI (mp-MRI)Radiomics

Identifiers

PMID40594237
PMCPMC12216350

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.